Long-Acting Cabotegravir and Rilpivirine is Noninferior to Oral ART as Maintenance Therapy for HIV-1 Infection: Week 48 Pooled Analysis From the Phase 3 ATLAS and FLAIR Studies

Conference Reports for NATAP

IAS 2019: Conference on HIV Pathogenesis
Treatment and Prevention
Mexico City
July 21-24 2019


Long-Acting Cabotegravir and Rilpivirine is Noninferior to Oral ART as Maintenance Therapy for HIV-1 Infection: Week 48 Pooled Analysis From the Phase 3 ATLAS and FLAIR Studies

	Reported by Jules Levin 10th IAS Conference on HIV Science (IAS 2019), 21-24 July 2019, Mexico City, Mexico LAAbbreviations 3TC, lamivudine; ABC, abacavir; AE, adverse event; ART, antiretroviral therapy; AZT, azidothymidine; BL, baseline; BMI, body mass index; CAB, cabotegravir; CAR, current antiretroviral; CI, confidence interval; CVF, confirmed virologic failure; DTG, dolutegravir; EFV, efavirenz; FTC, emtricitabine; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HIVTSQs, HIV Treatment Satisfaction Questionnaire (Status); HLA, human leukocyte antigen; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; ISR, injection site reaction; ITT-E, intention-to-treat exposed; LA, long-acting; LPV, lopinavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; r, ritonavir; RAL, raltegravir; RAM, resistance-associated mutation; RPV, rilpivirine; RT, reverse transcriptase; SVF, suspected virologic failure; TDF, tenofovir disoproxil fumarate; VL, viral load.